$6.7m to transform women’s hormonal health with AI-integrated app

Health tech company Hormona has raised a US$6.6m in its seed round that will drive the company’s expansion, help launch its innovative hormone tests, and grow B2B partnerships, while also strengthening its infrastructure, marketing and sales.

The funding will also support team growth to enhance customer experience, advancing Hormona’s mission to redefine hormone health globally.

Inka Mero (Voima Ventures), who has invested in multiple health-tech and mission-driven startups, and Gina King (SuperNode), a founding member of the female executive network Chief, will also join Hormona’s all-female board to support its next phase of growth.

Founded in 2020 by Karolina Löfqvist (CEO) and Jasmine Tagesson (COO), Hormona was created with clinical experts in endocrinology, gynaecology and nutrition to help users manage hormone-related conditions and better understand their health.

Hormona is tackling the critically underserved US$44bn women’s health market. The company was inspired by Löfqvist’s personal experience, in which a common hormonal condition derailed her life and went undiagnosed for years despite seeking extensive medical help.

Löfqvist’s story is far from unique: 80 per cent of women experience hormone-related issues.

Hormona has spent the last four years developing the first fully quantitative hormone tests of their kind, covering the full clinical range. which have over 90 per cent accuracy.

Hormona’s app also educates women on hormonal issues, and has been downloaded in more than 190 countries.

Hormona CEO and co-founder, Karolina Löfqvist, said: “For too long, women have had to suffer through hormonal issues, relying on trial and error and waiting until symptoms become unbearable.

“That’s no way to live. We built Hormona to change that – to give women control over their hormonal health without having to spend years suffering, as I did. This investment brings us one step closer to making real-time hormone tracking accessible to women everywhere without the need for multiple blood draws.

We’re proud to be leading the way and improving women’s health, one user at a time.”

Inka Mero, Managing Partner and Founder at Voima Ventures said: “At Voima Ventures, we seek out visionary teams and bold science that can redefine entire industries, and Hormona is exactly that: they are pioneering a global movement in women’s health.

“By tackling one of the most overlooked yet fundamental aspects of women’s well-being – hormonal health – they are giving millions of women the tools, data, and empowerment to take control of their bodies and lives.

We are incredibly proud to stand beside Hormona as they lead this health revolution.”

Gina King, partner at SuperNode Global VC, said: “The future of women’s health is proactive, data-driven, and deeply personalized – and Hormona is making that future a reality.

They’re bringing cutting-edge innovation to an area long overlooked by investment and technology, turning hormone health from guesswork into precision. At Supernode Global, we invest in companies that empower people in how they live – and Hormona exemplifies that mission.

By providing women with insights that were once out of reach, Hormona is transforming the landscape of healthcare. They represent exactly the kind of world-changing platform we’re proud to support as they scale globally and help millions of women live to their fullest potential.”